Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Tuesday 19 February, 2019

GlaxoSmithKline PLC

Director/PDMR Shareholding Replacement

RNS Number : 5124Q
GlaxoSmithKline PLC
19 February 2019
 

GlaxoSmithKline plc (the 'Company')

 

Transaction notification

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.0000

32,596 (Deferred)

 

 

£0.0000

19,234 (Matching)

 

 

 

 

 

d)

Aggregated information

 

Aggregated volume Price

51,830

£0.0000

e)

Date of the transaction

2019-02-18

f)

Place of the transaction

 

n/a

 

 

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 18 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£15.756

 15,345 (Deferred)

 

 

£15.756

 9,053 (Matching)

 

 

 

 

 

d)

Aggregated information

 

Aggregated volume Price

24,398

£15.756

e)

Date of the transaction

2019-02-18

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

  

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Connor

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

  

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.0000

11,073 (Deferred)

 

 

£0.0000

6,534 (Matching)

 

 

 

 

 

d)

Aggregated information

 

Aggregated volume Price

17,607

£0.0000

e)

Date of the transaction

2019-02-18

f)

Place of the transaction

 

n/a

 

 

 

 

  

1.

Details of PDMR/person closely associated with them ('PCA')

 

a)

Name

Mr R Connor

 

b)

Position/status

President, Global Vaccines

 

c)

Initial notification/

amendment

Initial Notification

 

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

GlaxoSmithKline plc

 

b)

LEI

5493000HZTVUYLO1D793

 

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

 

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

  

 

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 18 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£15.756

5,218 (Deferred)

 

 

£15.756

3,079 (Matching)

 

 

 

 

 

d)

Aggregated information

 

 

Aggregated volume

Price

8,297

£15.756

 

e)

Date of the transaction

2019-02-18

 

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

             
 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

  

 

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.0000

43,044 (Deferred)

 

 

£0.0000

25,398 (Matching)

 

 

 

 

 

d)

Aggregated information

 

Aggregated volume Price

68,442

£0.0000

e)

Date of the transaction

2019-02-18

f)

Place of the transaction

 

n/a

 

 

  

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

  

 

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 18 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£15.716

  20,263 (Deferred)

 

 

£15.716

11,955 (Matching)

 

 

 

 

 

d)

Aggregated information

 

Aggregated volume

Price

32,218

£15.716

e)

Date of the transaction

2019-02-18

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.0000

9,064 (Deferred)

 

 

£0.0000

5,349 (Matching)

 

 

 

 

 

d)

Aggregated information

 

Aggregated volume Price

14,413

£0.0000

e)

Date of the transaction

2019-02-18

f)

Place of the transaction

 

n/a

  

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

  

 

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 18 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£15.7215

  4,271 (Deferred)

 

 

£15.7215

2,521 (Matching)

 

 

 

 

 

d)

Aggregated information

 

Aggregated volume Price

6,792

£15.7215

e)

Date of the transaction

2019-02-18

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHDMGMZFLRGLZM

a d v e r t i s e m e n t